La bourse est fermée
  • CAC 40

    5 609,15
    +34,79 (+0,62 %)
     
  • Euro Stoxx 50

    3 539,27
    +22,17 (+0,63 %)
     
  • Dow Jones

    30 218,26
    +248,74 (+0,83 %)
     
  • EUR/USD

    1,2127
    -0,0022 (-0,18 %)
     
  • Gold future

    1 842,00
    +0,90 (+0,05 %)
     
  • BTC-EUR

    15 685,40
    -30,38 (-0,19 %)
     
  • CMC Crypto 200

    365,19
    -14,05 (-3,71 %)
     
  • Pétrole WTI

    46,09
    +0,45 (+0,99 %)
     
  • DAX

    13 298,96
    +46,10 (+0,35 %)
     
  • FTSE 100

    6 550,23
    +59,96 (+0,92 %)
     
  • Nasdaq

    12 464,23
    +87,05 (+0,70 %)
     
  • S&P 500

    3 699,12
    +32,40 (+0,88 %)
     
  • Nikkei 225

    26 751,24
    -58,13 (-0,22 %)
     
  • HANG SENG

    26 835,92
    +107,42 (+0,40 %)
     
  • GBP/USD

    1,3438
    -0,0015 (-0,11 %)
     

Sjogren’s Syndrome - Epidemiology Forecast to 2029

ReportLinker
·3 min de lecture

Summary Sjögren’s syndrome (SS) is a chronic autoimmune disease, characterized by immune cells attacking and destroying the glands that produce tears and saliva (NIH, 2019).

New York, Nov. 06, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Sjogren’s Syndrome - Epidemiology Forecast to 2029" - https://www.reportlinker.com/p05982880/?utm_source=GNW
It results in two major clinical manifestations: keratoconjunctivitis sicca (dry eyes) and xerostomia (dry mouth), more broadly known as sicca syndrome (Arthritis Foundation, 2019).

It can be classified into two types, primary and secondary SS. Primary SS (pSS) is seen in the absence of any other autoimmune disease (Salliot et al., 2007). Those most at risk of disease are women ages 40 and older (Johns Hopkins University, 2020).

Through an extensive literature review and analysis of recent and historical data, Epidemiologists have provided the most reliable and up-to-date forecast for SS in the 7MM.Epidemiologists performed a literature review, in both English and country-specific languages, to provide the most thorough search for SS data.

The forecast provides detailed, clinically relevant segmentations of the SS population, with pSS prevalence, sSS prevalence, and ESSDAI proportions included in all markets.

Epidemiologists have forecast the diagnosed prevalent cases of SS in the 7MM to increase from 1,630,861 in 2019, to 1,753,781 in 2029, with an annual growth rate (AGR) of 0.75%. In 2019, Epidemiologists estimated 1,111,294 diagnosed prevalent cases of pSS and 519,567 diagnosed prevalent cases of sSS. For systemic involvement of pSS defined by ESSDAI, Epidemiologists showed across the 7MM, the largest proportion of cases reported low-activity (ESSDAI<5) (70.20%) and the smallest proportion of cases reporting high-activity (ESSDAI?14) (5.59%). Epidemiologists predict that if other markets identify and address gaps in the diagnosis of SS as well as advocate for more dedicated SS research, similar to the UK, the rate of diagnosis will increase over time.

Scope
- The Sjögren’s Syndrome Epidemiology Report provides an overview of the risk factors, comorbidities, and global trends of Sjögren’s Syndrome (SS) in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
- The report includes a 10-year epidemiological forecast for diagnosed prevalent cases of pSS and sSS, with pSS segmented by sex and by age (18-29 years and for ages 30 years and older by 10-year age groups up to 80 years and older). Diagnosed prevalent cases of pSS are further segmented by systemic activity level using the ESSDAI classification.
- The SS epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in SS

Reasons to Buy
The SS Epidemiology series will allow you to -
- Develop business strategies by understanding the trends shaping and driving the global SS markets.
- Quantify patient populations in the global SS markets to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for SS therapeutics in each of the markets covered.
- Understand magnitude of systemic involvement of pSS defined by ESSDAI.
Read the full report: https://www.reportlinker.com/p05982880/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001